Effective targeting of the ubiquitin-like modifier NEDD8 for lung adenocarcinoma treatment.


Journal

Cell biology and toxicology
ISSN: 1573-6822
Titre abrégé: Cell Biol Toxicol
Pays: Switzerland
ID NLM: 8506639

Informations de publication

Date de publication:
08 2020
Historique:
received: 25 06 2019
accepted: 13 11 2019
pubmed: 8 1 2020
medline: 12 6 2021
entrez: 8 1 2020
Statut: ppublish

Résumé

Protein neddylation, a process of conjugating neural precursor cell expressed, developmentally downregulated 8 (NEDD8) to substrates, plays a tumor-promoting role in lung carcinogenesis. Our previous study showed MLN4924, an inhibitor of NEDD8 activating enzyme (E1), significantly inhibits the growth of multiple cancer cells. However, resistance can develop to MLN4924 by mutation. Therefore, it is important to further understand how NEDD8 acts in lung cancer. In the present study, we demonstrated NEDD8 is overactivated in lung cancers and confers a worse patient overall survival. Furthermore, we report that in lung adenocarcinoma cells, NEDD8 depletion significantly suppressed lung cancer cell growth and progression both in vitro and in vivo. Mechanistic studies revealed that NEDD8 depletion induced the accumulation of a panel of tumor-suppressive cullin-RING ubiquitin ligase substrates (e.g., p21, p27, and Wee1) via blocking their degradation, triggering cell cycle arrest at G

Identifiants

pubmed: 31907687
doi: 10.1007/s10565-019-09503-6
pii: 10.1007/s10565-019-09503-6
doi:

Substances chimiques

Cyclopentanes 0
NEDD8 Protein 0
NEDD8 protein, human 0
Pyrimidines 0
Ubiquitin 0
pevonedistat S3AZD8D215

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

349-364

Auteurs

Yanyu Jiang (Y)

Cancer Institute, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200032, China.

Wei Cheng (W)

Cancer Institute, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200032, China.

Lihui Li (L)

Cancer Institute, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200032, China.

Lisha Zhou (L)

Cancer Institute, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200032, China.
Department of Biochemistry, Medical College, Taizhou University, Taizhou, Zhejiang, 317000, China.

Yupei Liang (Y)

Cancer Institute, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200032, China.

Wenjuan Zhang (W)

Cancer Institute, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200032, China.
Cancer Institute, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.

Wenlian Chen (W)

Cancer Institute, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200032, China.

Shiwen Wang (S)

Department of Laboratory Medicine, Huadong Hospital Fudan University, Shanghai, China.

Hu Zhao (H)

Department of Laboratory Medicine, Huadong Hospital Fudan University, Shanghai, China.

Guoan Chen (G)

School of Medicine, Southern University of Science and Technology, Shenzhen, China.

Wenjun Zhou (W)

Institute of Digestive Diseases, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.

Guang Ji (G)

Institute of Digestive Diseases, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.

Yanmei Zhang (Y)

Department of Laboratory Medicine, Huadong Hospital Fudan University, Shanghai, China. 15618653286@163.com.

Robert M Hoffman (RM)

Department of Surgery, University of California, San Diego, CA, USA.
Anticancer Inc, San Diego, CA, USA.

Mingsong Wang (M)

Department of Cardiothoracic Surgery, Xinhua Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China. 13764517021@163.com.

Lijun Jia (L)

Cancer Institute, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200032, China. ljjia@shutcm.edu.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH